- Net sales amounted to 0.6 (0.6) MSEK
- Operating profit for the period was -9.8 (-10.8) MSEK
- Net income was -9.8 (-10.8) MSEK corresponding to earnings per share of
- Cash flow from operating activities was -6.1 (-11.7) MSEK
- Cash and cash equivalents amounted to 27.5 (23.3) MSEK
Important events January – March
- The R&D project with J&J has moved to the next phase.
- A financing agreement of up to 40.8 MSEK signed with Nice&Green
Significant events after the reporting period
Max Mittereggerand John Lundare proposed as a new member of the LIDDS Board of Directors. Max Mittereggerwill acquire, as part of his appointment to the LIDDS Board of Directors, shares with a total value of 4.5 MSEK. It is proposed that this be done by means of a directed issue of 750,000 shares at a subscription price of SEK 6, which is the LIDDS share price on the Nasdaq First North Growth Market at the time for a firm commitment to subscribe for the shares. The directed issue of shares is subject to the approval of the annual general meeting of shareholders.
At the beginning of 2022, we had several important announcements. At the beginning of January, we announced that the research collaboration with
We also presented the next step in the development of our nanodotax project which is docetaxel formulated with nanozolids. We will conduct a shorter clinical study to assess the immunological effects observed in the Phase I clinical study NZ-DTX-001. The study showed the activation of systemic inflammatory biomarkers that are believed to improve treatment conditions with so-called checkpoint inhibitors. Preliminary results indicate that local treatment with nanodotax could stimulate the immune system of patients in such a way that it could attack even distant metastases. Based on the positive results of the Phase I study, we elected to support sponsorship of the previously approved investigator-sponsored trial in patients with prostate cancer. We expect to be able to start recruiting patients very soon and I look forward to the results as the study will provide important insight into the mechanism of action and how the project will progress through clinical development for the group of patients and the indication.
I note that there is great interest in treatment targeted at TLR9 because
In order to be able to continue the positive development of the project portfolio, secure financing is of great importance. Therefore, we announced in February that
I am happy to have been able to meet both shareholders and other stakeholders during the first months of the year. We did this both at Redeye’s Fight Cancer Day in January and at the much-loved Capital Markets Day (CMD) we hosted in March. At CMD, the focus was on our research and development – the heart of the business. I appreciate your commitment and interest and look forward to seeing you again. In June, we will be right to spread the word about
My goal going forward is to maintain the good foundations we have carefully established for the business in 2021 and early 2022. We will accelerate the work of developing effective solutions for local drug delivery and develop projects that generate the greatest opportunities for future collaborations. and agreements.
Thank you for your support.
The interim report is available on the company’s website https://liddspharma.com/en/investors/financial-reports/